Sorrento acquires further rights to Cynviloq to Include Australia, Canada and Mexico
US cancer drug developer Sorrento Therapeutics (Nasdaq: SRNE) has obtained exclusive rights to Cynviloq (marketed as Genexol-PM in South Korea and other countries) in Australia, Canada and Mexico from Samyang Biopharmaceuticals, a South Korean corporation.
Financial terms of the agreement were not disclosed. Sorrento already has exclusive rights from Samyang for Cynviloq in the USA and the 27 countries of the European Union (The Pharma Letter May 14, 2013). Terms of that deal were also not revealed.
"We have made significant progress carving out the clinical and regulatory path for the Cynviloq program, and we continue to build on the global commercial opportunity for this product," said Henry Ji, president and chief executive of Sorrento, adding: "With these expanded rights, Sorrento now covers the vast majority of its targeted Cynviloq markets".
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze